Canine Health Genetics: Epilepsy & Osteosarcoma Risk Studies

The Genetic Clockwork of Canine Health: Two Studies Illuminate Breed-Specific Risks

A University of California, Davis study identified specific genes expressed differently in the blood of Belgian Shepherds with idiopathic epilepsy. At the same time, research from Duke University and the University of Southern California discovered a genetic variation near a gene called GRB10 that influences bone growth and increases osteosarcoma risk across dog breeds and humans. Together, these investigations move beyond simply mapping DNA sequences to reveal the active biological pathways that create disease susceptibility, offering a clearer picture of why certain breeds face higher risks for specific conditions.

Belgian Shepherd Epilepsy: Pinpointing Active Genes Beyond the Risk Haplotype

Researchers from UC Davis, led by Kinsey N., Belanger J.M., and Oberbauer A.M., knew Belgian Shepherds carry a genetic risk marker for idiopathic epilepsy (IE) on chromosome 14. Their 2024 study asked a more functional question: what genes are actively turned on or off in these dogs? Using RNA sequencing on whole blood samples, they compared dogs with IE to healthy controls.

They found two seizure-implicated genes, MFSD2A and a probable pseudogene of RPL19, were upregulated, meaning their activity was increased in epileptic dogs. Simultaneously, a suite of genes in the interferon signaling pathway—a key part of the immune system’s antiviral response—were downregulated. The study also connected the dots to the known CFA14 risk haplotype, showing it was associated with changes in the expression of four other genes (CLIC1, ACE2, PIGN, EPDR1) involved in epilepsy and the Wnt/β-catenin signaling pathway, which is critical for cell communication and development.

This work confirms that the genetic risk for IE in Belgian Shepherds isn’t confined to a single silent mutation. It manifests as a detectable signature of altered gene activity in pathways directly related to neurological function and immune regulation.

The GRB10 Genetic Link: Where Bone Growth and Cancer Risk Intersect

A separate multi-institutional study published in Cancer Epidemiology, involving Duke University and the University of Southern California, identified a genetic connection between skeletal development and a deadly cancer. The team, including Lucas S.E., Yang T., and Walsh K.M., analyzed genetic data from dogs and humans with osteosarcoma, a bone cancer common in large and giant dog breeds like Greyhounds, Rottweilers, and Great Danes.

They discovered that a specific genetic variation near the GRB10 gene is associated with both increased osteosarcoma risk and a tendency for taller stature and longer limb bones. GRB10 is a known growth regulator. This finding suggests the same genetic mechanism that drives rapid bone growth during development may also, in some cases, predispose the rapidly dividing cells in growth plates to cancerous transformation later in life. The effect was observed across species, highlighting a conserved biological pathway.

This research provides a mechanistic explanation for a long-observed veterinary correlation: large, fast-growing breeds are at highest risk for osteosarcoma. It moves the understanding from observation to a specific molecular hypothesis.

From Genetic Code to Clinical Understanding

These studies demonstrate a critical evolution in canine genetic research. It’s no longer just about finding a “faulty” gene sequence. Scientists are now analyzing how genetic variations change the actual operation of biological systems—which genes are dialed up, which are dialed down, and in which pathways.

The Belgian Shepherd research shows IE involves a combination of disrupted neural and immune signaling. The interferon pathway downregulation is particularly interesting, as it suggests a potential link between immune function and seizure threshold, an area of growing focus. The osteosarcoma study directly ties a quantifiable physical trait (growth rate and size) to a molecular cancer risk, explaining why selective breeding for extreme size can have unintended health consequences.

A limitation of both studies is that they identify associations and altered states, not absolute certainties. Not every dog with the CFA14 haplotype will develop epilepsy, and not every large dog with the GRB10-associated variant will get osteosarcoma. Other genetic and environmental factors modify the final risk. However, they provide the strongest evidence yet for the specific biological routes these diseases take.

Practical Applications for Breeders and Veterinarians

For those invested in canine wellness, this research has tangible implications. Breeders of Belgian Shepherds and other breeds prone to IE now have a more detailed picture of the condition’s biology. This knowledge can prioritize health testing and inform mating selections aimed at gradually reducing the prevalence of high-risk genetic combinations, while acknowledging the complex inheritance suggested by multiple gene pathways.

The osteosarcoma finding offers a potential tool for screening. In the future, genetic tests for the GRB10-associated variant could help identify at-risk individuals within large breeds. Owners and veterinarians could then implement more vigilant monitoring for early signs of lameness or pain. This study also reinforces the importance of considering health alongside conformation; breeding for moderate, healthy bone structure may inherently reduce osteosarcoma risk.

Ultimately, this research feeds into a broader movement toward precision veterinary medicine. Understanding the exact pathways involved in a disease opens the door to developing targeted treatments. For instance, if interferon signaling is deficient in epileptic Belgian Shepherds, could immune-modulating supplements or therapies be explored as part of a management plan? As genetic insights become more functional, they transition from abstract risk statistics to actionable biological knowledge.

Frequently Asked Questions

Can I test my Belgian Shepherd for the epilepsy genes found in this study?

Currently, direct-to-consumer tests for the specific gene expression signatures identified in this RNA study are not available. However, some genetic testing panels do screen for the known risk haplotype on chromosome 14 mentioned in the research, which can provide a partial risk assessment.

Does this mean small dogs are safe from osteosarcoma?

While osteosarcoma is much more common in large and giant breeds, the study identified a genetic risk factor related to growth. Small dogs can still develop osteosarcoma, but their overall risk is significantly lower, and the specific GRB10-associated variant is less relevant in those populations.

If my dog has a genetic risk, does it mean they will definitely get the disease?

No. These studies identify predispositions, not destinies. A genetic risk factor increases likelihood, but other genes, environmental factors, nutrition, and chance all play a role in whether a condition actually develops. They are tools for awareness and proactive care, not a diagnosis.

Sources:
https://pubmed.ncbi.nlm.nih.gov/39596674/
https://pubmed.ncbi.nlm.nih.gov/38871555/
https://pubmed.ncbi.nlm.nih.gov/38710903/